This systematic review evaluates the compelling evidence for using tranexamic acid (TXA) to reduce perioperative blood loss in patients undergoing High Tibial Osteotomy (HTO). By synthesising data from multiple clinical studies, the research provides a clear and powerful case for incorporating TXA into standard surgical practice to enhance recovery outcomes, mitigate complications, and reduce the burden on blood supply systems.
Study Methodology and Key Findings
The study consolidated data from 11 distinct research papers, encompassing a substantial patient population of 974 individuals. These studies compared the outcomes of patients who received tranexamic acid against those who received a placebo or a different dosage of the drug. The results demonstrated a statistically significant and clinically meaningful reduction in blood loss among patients who were administered TXA.
The key findings were quantified using a standardised mean difference (SMD), a metric that allows for a direct comparison of results across different studies. The analysis showed:
- Total Blood Loss: The standardised mean difference (SMD) in total blood loss was -2.37 (95% CI -3.67, -1.07; P = 0.0004), a robust finding that confirms the efficacy of TXA in reducing bleeding.
- Haemoglobin Drop: The SMD for the decrease in haemoglobin on the first postoperative day was -0.97 (95% CI -1.19, -0.75; P < 0.00001), indicating that TXA helps patients maintain a healthier blood profile after surgery.
These data points provide strong evidence that tranexamic acid is not just marginally effective but has a profound impact on a patient’s physiological response to surgery.
Clinical and Socioeconomic Implications
The findings of this systematic review hold significant clinical and socioeconomic implications. Reducing perioperative blood loss is a primary objective for surgeons as it directly correlates with a lower risk of complications, such as the need for blood transfusions or post-surgical anaemia.
Beyond the immediate medical benefits, the use of tranexamic acid in HTO procedures can lead to a shorter duration of hospital stays and a smoother recovery trajectory for patients. This is particularly beneficial given the ongoing global constraints on blood supplies, as it reduces the demand for donated blood products. By conserving this critical resource, surgeons can optimise care not only for the individual patient but for the broader healthcare system. This makes TXA administration a compelling strategy that aligns patient-centric care with a wider, more responsible management of medical resources.
The research confirms that TXA administration in HTO is a safe and effective way to enhance recovery, minimise complications, and reduce hospital stay duration, which is particularly beneficial given current blood supply constraints.
For a comprehensive analysis of the full data, methodology, and conclusions, the complete research paper is available at:
Clinical Outcomes Following Use of Tranexamic Acid in High Tibial Osteotomy: A Systematic Review
